OMTX-705 is under clinical development by Oncomatryx Biopharma and currently in Phase I for Leiomyosarcoma. According to GlobalData, Phase I drugs for Leiomyosarcoma have a 92% phase transition ...

OMTX-705 is under clinical development by Oncomatryx Biopharma and currently in Phase I for Gastric Cancer. According to GlobalData, Phase I drugs for Gastric Cancer have a 74% phase transition ...

The BD+C editorial team asked the 2024 Architecture Giants to submit their single-biggest firm innovation or business move ...

INR:4690. football jersey design with shorts Eli Lilly's innovative combination therapy for lung cancer is approved in Europe, Gilead promotes ...

crix live Rongchang Biopharma passed the hearing of the Hong Kong Stock Exchange ... another "king bomb" and drug O is on the top of the gastric cancer "hill" China publicly solicits guidelines for ...

The MedTech sector faced considerable challenges in 2024, making it a difficult year for investors. In the year, the slow ...